Reaction Biology to Present Data at AACR 2023 Showcasing Expansive Capabilities in Immuno-Oncology Drug Discovery and Development
~ New Data will be Presented on the Company’s Innovative Assay Technologies, Preclinical Profiling Models and Proprietary Screening Platforms ~
~ Reaction Biology will be at Booth #1527 in the AACR 2023 Exhibit Hall ~
Reaction Biology Selected for Participation in National Chemical Biology Consortium to Support Drug Discovery Utilizing Surface Plasmon Resonance (“SPR”) Technology
Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery services, today announced that it has been selected to participate as a Specialized Center in the Chemical Biology Consortium (CBC), the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR).
Reaction Biology Acquires Bioassay GmbH Increasing Large Molecule Capabilities Within Its Robust Portfolio of Drug Discovery and Development Services
~ Bioassay GmbH, an Independent Contract Laboratory, Specializes in the Development, Validation and Routine Performance of Bioanalytical Assays ~
~Transaction Includes Acquisition of Bioassay GmbH Subsidiary, Peptide Specialty Laboratories GmbH, a Provider Specializing in the Synthesis and Production of Customized Peptides and Specific Antibodies~
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd ~
~ Transaction Expands Reaction Biology’s Capabilities to Provide Customers with Solutions in Both the Discovery and Development of New Drug Candidates ~
Reaction Biology Announces Expansion of Executive Leadership Team with Key Appointments in Commercial and Human Resources Functions
Reaction Biology today announced the expansion of its Executive Leadership team with the appointments of Alan Findlater to the position of Chief Commercial Officer (CCO) and Emily Doyle to the position of Chief People Officer (CPO). Mr. Findlater and Ms. Doyle will also serve as members of the Executive Committee, effective immediately. These new appointments strengthen Reaction’s commercial and human resources functional areas.
New Data at AACR Showcase Reaction Biology’s Innovative Approach to Oncology Drug Discovery Services
New diacylglycerol kinase assay panel provides researchers for the first time with ten new lipid
New systems biology approach enhances preclinical characterization of the WEE-1 inhibitor
Reaction Biology Announces Appointment of Richard S. Kollender to Chief Financial Officer and Chief Business Officer
Reaction Biology today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company’s next stage of growth.
Reaction Biology Launches InVEST Screening Panel to Identify Drug Toxicity Effects of New Drug Candidates
Early Safety Screening Tool Helps Drugmakers De-Risk Development and Optimize the Potential of Therapeutic Candidates
Reaction Biology Announces Closing of Growth Investment from Cobepa and Chief Executive Officer Transition
John H. Johnson Appointed to Chief Executive Officer and Board Director of Reaction Biology
Reaction Biology Well Positioned to Expand Upon Global Drug Discovery Capabilities
Reaction Biology announces Integrated Drug Discovery solutions: The Reaction Oncology Platform
We are happy to announce that our scientists have created a comprehensive platform for integrated drug discovery: The Reaction Oncology Platform, to support every step of your cancer drug discovery project from target research to lead optimization. The value of the Reaction Oncology Platform lies in our global network strategic partners and their scientific expertise. Let’s discover together.
Because we care.
We have taken our engagement in drug discovery from providing services to our clients to providing financial aid to advance drug discovery against pediatric cancer. To this end, we support the St. Jude Children’s Research Hospital and the German Kids Cancer Fund with a donation of $50,000. Let’s find cures together.
COVID-19 /SARS-CoV2 update
all Reaction Biology research facilities are and remain fully operational under safe work environment guidelines. Our business will not close due to lockdown restrictions in Europe. Our sales staff and business development team are happy to discuss any project with you. Please reach out!
Certificate ISO 9001
Reaction Biology Europe GmbH has established and applies a Quality Management System (Certificate ISO 9001) for Development, production and sale of recombinant protein products, biochemical and cellular assay services as well as in vivo testing services for the development of new drugs targeting diseases, for example in oncology.
Cooperation with 4HF Biotec to provide new Bioinformatic Cell Service
In cooperation with the bioinformatics firm 4HF Biotec, we announce the offering of a combination of the ProLiFiler cell panel screening service with 4HF‘s bioinformatic evaluation of the drug‘s profile.
ProQinase is now Reaction Biology Europe
ProQinase rebranding into Reaction Biology Europe GmbH was performed completing the process of acquiring ProQinase. As this only represents a change of name, all contracts with former ProQinase remain valid and binding. All ProQinase products and services are continued and available within the Reaction Biology portfolio.
Reaction Biology and Pharmacore Lab announce China outreach
We are pleased to announce a joint collaboration agreement with PharmaCore Labs, a firm located in Haimen, China. PharmaCore Labs will increase our visibility in China with business support and development personnel. We will make our full suite of biochemical, cell-based, and in vivo assay services available to PharmaCore Labs for distribution in China. The arrangement is designed to make it more convenient for Chinese firms to use our services, and also allows us to invoice in Yuan.
Integrated Drug Discovery Project with Bionetix
Bionetix, ProQinase, and MercachemSyncom announce a joint research project from target Identification to clinical study for a new AML drug.
Establishment of advanced oncology profiling cascade with Gotham
Announcing exciting news about ProQinase’s collaboration with Gotham Therapeutics in the field of custom assay development for compounds addressing three different mRNA-modifying targets. We established an advanced oncology profiling cascade to progress Gotham’s portfolio of epitranscriptomic drug candidates.
Reaction Biology Receives Subcontract for Biophysical Drug Discovery
Reaction Biology has received a subcontract from Leidos Biomedical Research, Inc., which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute. Under the subcontract, RBC will work on an early stage drug discovery project for the National Cancer Institute’s Experimental Therapeutics (NExT) program using Surface Plasmon Resonance (“SPR”) technology.
ProQinase GmbH Purchased by Reaction Biology Corporation
On February 4, 2019, Reaction Biology Corporation (RBC) (www.reactionbiology.com) and ChinaEquity Group (CEG) (www.chinaequity.net) announced the completion of a stock swap transaction whereby RBC has acquired all the shares of ProQinase GmbH.
The combination of RBC and ProQinase will create the world’s leading kinase drug discovery company, with a diverse offering and operations in Europe and the United States. The combined companies plan to continue expanding operations in both facilities and adding to their product offerings. In addition, RBC plans to open a China-based subsidiary in collaboration with its significant new shareholder, CEG.
Reaction Biology Announces New NanoBRET Technology in Collaboration with Promega
NanoBRETTM, a new cell based profiling service for drug discovery announced by Reaction Biology Corporation and Promega Corporation will allow more researchers to better prioritize compounds earlier.
Reaction Biology Joins the Fight Against DIPG with M4K Pharma
Reaction Biology Corporation has partnered with M4K Pharma, an open science drug discovery and development company, in the fight against diffuse intrinsic pontine glioma (or DIPG), a rare pediatric brain cancer with no curative therapies.
Reaction Biology launches ion channel division
Reaction Biology Corporation has launched a new division to provide ion-channel discovery services. RBC has completed an acquisition of ion-channel assets from a Pennsylvania-based firm, has retained their senior scientist personnel with decades of electrophysiology experience and has begun providing services.
ProQinase GmbH is now ISO 9001:2015 certified
ProQinase constantly works on the improvement of the quality of its products, services and customer relationship. Therefore, the company is now officially certified according to DIN EN ISO 9001:2015. The certification represents another milestone in our continued commitment to highest quality standards and customer satisfaction.
New Distributor in China
4A Biotech Co. Ltd. and ProQinase have signed an agreement for distribution of ProQinase’s products in China. 4A Biotech Co. Ltd. has been appointed as exclusive distributor of ProQinase kinase-related products under ProQinase’s brand name in the territory of the PR of China (excluding Taiwan). All Chinese customers interested in ordering such products are kindly requested to contact [email protected].
Reaction Biology Announces Bromodomain Grant
Reaction Biology Corporation has been awarded a Phase ISBIR grant from the National Center for Advancing Translational Sciences to create tools and techniques for bromodomain drug discovery.
Reaction Biology Receives NIH Grant Award for Epigenetic Database
Reaction Biology Corporation has been awarded a Phase ISBIR grant from the National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions.
Reaction Biology and Cisbio Bioassays Sign Distribution Agreement
Reaction Biology Corporation has signed an agreement for Cisbio Bioassays, a cutting-edge biotechnology company in the field of products and services for human in vitro diagnostics and pharmaceutical research, to distribute its epigenetic proteins.
Reaction Biology Top-Ranked in Kinase Profiling Survey
Reaction Biology Corporation has received the highest number of positive ratings in a recent industry survey.
Reaction Biology Corporation Announces New Epigenetic Production Facility
Reaction Biology Corporation opens a new protein production facility. The new purpose-built space is situated almost adjacent to RBC’s current drug-screening facilities in the Great Valley Corporate Center in Malvern, Pennsylvania.
RBC’s methyltransferases the preferred enzymes for BellBrook Labs’ Transcreener technology
Reaction Biology and BellBrook Labs are working together to make it easier to screen and profile methyltransferases. Reaction Biology has produced more than 30 recombinant human methyltransferases to the most stringent purity and activity requirements in the industry.
Reaction Biology Now Offers Recombinant Methyltransferases to Complement Its Existing Epigenetic Services
Reaction Biology today announced the rollout of a new product line, recombinant proteins for epigenetic research. The initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
ProQinase is part of the German research alliance BioTag to develop new biomarker screens to measure tumor response to innovative protein kinase inhibitors
Proteome Sciences R&D GmbH and Co. KG, Frankfurt, ProQinase GmbH, Freiburg, and the NMI Natural and Medical Sciences Institute, today announced the start of BioTag, a three-year grant project supported by the German Federal Ministry of Research (BMBF) as part of the KMU-Innovative-2 Program, to establish and to validate new workflows for the development and early clinical evaluation of inhibitors targeting tumor protein kinases.
Please read the press release here.
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
CRELUX and ProQinaseannounced today that they have entered into a joint agreement to supplycustomers with crystal-grade proteinkinases and readily available kinasecomplex structures.
Read the press release here.
ProQinase will identify novel biomarkers for anti-tumour therapies as member of the EU-research consortium „ANGIOTARGETING - European Consortium for Tumour Angiogenesis Research”
Reliable prediction about the success or failure of new anti-tumortherapies can be providedby so-called biomarkers. Biomarkers are patientcharacteristics, e.g. presence of specific proteins, of which the amount changesas a result of a therapeutic intervention.Detection of biomarkers in peripheralblood of tumor patientscan represent a simple and non-invasive method todetermine the success or failureof a given treatment.As part of an EU-funded research programProQinase, a business division ofKTB Tumorforschungsgesellschaft mbH at the Tumorbiology Center Freiburg,will identify novel potential biomarkers.
Reaction Biology Corp Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development
Reaction Biology today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions. The grant funds the use of Reaction Biology’s DiscoveryDot microarray technology for high throughput screening of kinases.
Please read press release here.
Key Organics Ltd and Reaction Biology Corp Announce New Library Screening Format
Key Organics Ltd. and Reaction Biology Corp. today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for “rental” screening on Reaction Biology’s DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright.
Read the press release here.
ChemDiv, Inc. and ProQinaseGmbH to Partner in Lead Discovery and Preclinical Development in Oncology
ChemDiv, Inc. of San Diego, CA, and ProQinase GmbH of Freiburg, Germany, announced that they have signed an agreement to establish a partnership in the discovery and preclinical development of new kinase inhibitors.
Read the press release here.
Reaction Biology Corporation and Key Organics Ltd Announce Drug Discovery Collaboration
Reaction Biology Corp. and Key Organics Ltd. today announced that they have created a Joint Venture to engage in high throughput drug discovery.
The purpose of the collaboration is to identify a series of compounds with the potential of becoming new drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets. Key supplies diverse sets of compounds synthesized in-house using classical organic procedures optimized for primary screening of druggable targets. Reaction Biology’s DiscoveryDot™ microarray technology reduces screening volumes to one nanoliter size, allowing large scale screening at low cost.
Please read the press release here.
Reaction Biology Corporation Awarded Phase II SBIR Grant for Drug Discovery
Reaction Biology Corp. today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot™ High Throughput Screening technology for drug discovery.
The $750,000 grant originates from the National Institute of Dental and Craniofacial Research and funds the use of RBC’s DiscoveryDot™ microarray technology for high throughput screening of caspases and other proteases. The DiscoveryDot™ technology is capable of screening up to 6,600 individual reactions on a 1-by-3 inch glass slide. The one nanoliter reaction volume used by RBC represents one ten-thousandth the volume of conventional screening systems, and can potentially save millions of dollars on large scale screening campaigns through reagent savings, process costs, and labor reduction.
Caspases play pivotal roles in regulating cell apoptosis and represent targets of significant interest in craniofacial medicine and other areas. RBC’s ability to print large chemical compound libraries in hundreds of replicate copies for caspase and protease screening can accelerate early-stage lead identification at a fraction of the cost of conventional technology.
ProQinase and the University of Duesseldorf receive BMBF-Grant for German-Chinese Research Project for the discovery of novel drugs for the treatment of cancer and viral diseases
ProQinase GmbH at the Tumor Biology Center Freiburg,Germany, and the Institute of Pharmaceutical Biology and Biotechnology at the University ofDuesseldorf, Germany, announced the start of a research project for the discovery of novelanti-cancer drugs. In cooperation with the Universities of Beijing and Qingdao, China, theChinese Academy of Sciences and the Chinese biotech company Pason-Biotech, scientistswill isolate natural compounds from Chinese marine organisms, and investigate theirusefulness for the treatment of cancer and viral diseases.China offers an immense variety of marine organisms that represent a largely unexploredsource for natural compounds with medical potential. The project combines the expertise of theChinese scientists in the field of marine organisms and natural compound chemistry, theknowledge of the groups of Prof. Peter Proksch and Dr. Rainer Ebel of the University ofDuesseldorf in the area of natural compound purification and characterization with the know-howof the biotech companies in the field of drug development for viral infections (PasonBiotech) and cancer (ProQinase). The project will be supported by the German FederalMinistry of Research as part of its “Biotechnology Research and Technology-Programme” withabout 1 Mio. Euro in the next three years.
MorphoSys Antibodies by Design, ProQinase and Natural and NMI receive BMBF-promotion for Kinome-project
ProQinase GmbH, Freiburg, the NMI Natural and Medical Sciences Institute at the University of Tübingen, and Antibodies by Design, a division of MorphoSys AG, Munich, today announced the start of a joint project which could revolutionize the analysis of all human protein kinases – the human “kinome”.
Please read the press release here.
ProQinase participates in EU FP6Research Program „Protein Kinases –Novel Drug Targets of Post Genomic Era“
ProQinase GmbHhasreceived a grant from the 6thEuropean Framework Program(http://europa.eu.int/comm/research/fp6/index_en.html). The Biotech Company is participatingin the “ProKinaseResearch” consortium of 23 partners from eleven countriesand is coordinated by the University of Helsinki (www.proteinkinase-research.org). Aim of the research is the development of novel inhibitors of protein kinases. Such substances have applications for the treatment of various diseases such ascancer.
4SC and ProQinase collaborate on the discovery of new protein kinase inhibitors for cancer treatment.
4SC AG and ProQinase GmbH announced today a research collaboration to identify a new generation of protein kinase inhibitors as the basis for the development of new anticancer drugs. Protein kinases are key components of the signaling pathways of cells, including those pathways implicated in the development of tumors.
“ProQinase’s expertise in protein kinase research will provide an excellent starting point for the discovery process,” stated Dr. Ulrich Dauer, CEO of 4SC. “Because of these existing validated targets, we believe that this collaboration will quickly advance potential drug candidates through research into clinical trials.”
ProQinase will provide disease-relevant protein kinase targets using its proprietary integrated technology platform, including cell-based assays and in vivo models. 4SC will apply its virtual High Throughput Screening technology, 4SCan® in combination with its medicinal chemistry capabilities. Identified lead candidate drugs will be synthesized and provided to ProQinase for biological screening and pharmacological testing.
“4SC, with its cost and time-saving discovery process, represents an ideal partner to rapidly deliver validated lead drug candidates,’’ said Dr. Christoph Schächtele, Managing Director of ProQinase. “Our close proximity to the Tumor Biology Center in Freiburg will greatly facilitate taking these potential new cancer drugs into clinical trials.”
ProQinase receives "Freiburg Innovation Award 2002" for its Integrated Technology Platform Protein Kinases
The “Freiburg Innovation Award” is given biannually to companies of the region that feature innovative technologies and products that make them leaders in their respective fields. The jury, consisting of members from science, politics, and finance, reviewed 47 applications and selected three companies for their innovative technologies. ProQinase is the only biotech company receiving this year’s award.